An international team of researchers led by Dr. Eleanor Fish, Scientist Emeritus at the Toronto General Hospital Research Institute, UHN, and professor in the University of Toronto‘s Department of Immunology, has shown for the first time that an antiviral drug can help speed up the recovery of COVID-19 patients.
According to the new study, published Friday in Frontiers in Immunology, treatment with interferon(IFN)- a2b may significantly accelerate virus clearance and reduce levels of inflammatory proteins in COVID-19 patients.
The research team found that treatment with this drug, which has been used clinically for many years, significantly reduced the duration of detectable virus in the upper respiratory tract, on average by about seven days. It also reduced blood levels of interleukin(IL)-6 and C-reactive protein (CRP), two inflammatory proteins found in COVID-19 patients.
Dr. Fish says the research team considered IFN-a therapy for COVID-19 after they demonstrated interferon provided therapeutic benefit during the SARS outbreak of 2002 and 2003.
“Rather than developing a virus-specific antiviral for each new virus outbreak, I would argue that we should consider interferons as the ‘first responders’ in terms of treatment,” says Dr. Fish.
“Interferons have been approved for clinical use for many years, so the strategy would be to ‘repurpose’ them for severe acute virus infections.”
Boosting a natural defence mechanism
Interferons are a group of signaling proteins released by the human body in response to all viruses. As Dr. Fish explains, they are a “first line of defence.”
They target different stages of a virus’s life cycle, inhibiting them from multiplying. They also boost an immune response by activating different immune cells to clear an infection. Some viruses, however, can block this natural defense mechanism.
“But it is possible to override this block. If a virus blocks interferon production, then treating with interferon can offset this.”
Study details
The researchers conducted this exploratory study on a group of 77 patients with COVID-19 in Wuhan, China. These patients were admitted to Union Hospital, Tongii Medical College, between January 16 and February 20, 2020. They represented moderate cases of the disease as none of the patients required intensive care or prolonged oxygen supplementation or intubation.
Despite the study’s limitations of a small, non-randomized group of patients, the work provides several important and novel insights into COVID-19 disease, notably that treatment with IFN-a2b can accelerate viral clearance from the upper respiratory tract and also reduce circulating levels of inflammatory factors that are associated with severe COVID-19.
Dr. Fish says a randomized clinical trial is a crucial next step. According to her, a clinical trial with a larger group of infected patients who are randomized to treatment or placebo would further this research.
In the meantime, the findings from this study are the first to suggest therapeutic efficacy of IFN-a2b as an available antiviral intervention for COVID-19, which may also benefit public health measures by shortening the duration of viral clearance and therefore slowing the tide of the pandemic.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Recovery of COVID-19 patients
- Grocery store, restaurants, maybe a hotel. Inside Valley Children’s ambitious retail plans
They point out that a majority of the patients at the hospital (more than 70%) are beneficiaries of Medi-Cal, the state’s insurance program for low-income people. At least one expert in nonprofit ...
- NIH RECOVER makes long Covid data easier to access
The addition of RECOVER data to BDC can help ... It seeks to identify how people recuperate from Covid-19 and who is at risk for developing post-acute sequelae of SARS-CoV-2 (PASC). Researchers are ...
- COVID patient's strange symptoms save her from deadly undiagnosed diseases. Here's what doctors discovered.
Vicky Dennis had COVID in 2020 and went to the hospital with strange symptoms. Doctors found she had two undiagnosed, life-threatening diseases and that she needed a liver transplant to survive.
- Covid-19 Found in People’s Blood Months After Infection
A quarter of people had Covid-19 viral proteins in their blood up to 14 months after infection. These proteins in the blood indicate that SARS-CoV-2 keeps living in tissue reservoirs. The study used a ...
- NIH RECOVER Makes Long COVID Data Easier to Access - Deidentified Data from Thousands of Adults with Long COVID are Now Available to Researchers
NIH RECOVER Makes Long COVID Data Easier to Access - Deidentified Data from Thousands of Adults with Long COVID are Now Available to Researchers ...
Go deeper with Google Headlines on:
Recovery of COVID-19 patients
[google_news title=”” keyword=”recovery of COVID-19 patients” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Antiviral drug
- Can nasal Neosporin fight COVID? Surprising new research suggests it works
A potential treatment for COVID-19 may have been hiding in our medicine cabinets, a new study in PNAS has found ...
- Antiviral Combination Therapies Market Seizing Tomorrow Harnessing the Power of Future Market Size Trends
Antiviral Combination Therapies Market is valued approximately USD 40.4 billion in 2019 and is anticipated to grow with a healthy growth rate of more than $ over the forecast period 2020-2027.
- Hyundai Bioscience's antiviral for Dengue Fever to enter clinical trials in Brazil
Hyundai Bioscience announced on April 25th that, after multiple consultations with global clinical research organizations (CRO), it has decided to conduct clinical trials for its 'niclosamide-based ...
- Recommendations for the Prevention and Treatment of Influenza Using Antiviral Drugs Based on Cost–Effectiveness
Antiviral drugs can be used for the treatment of influenza and the prevention of seasonal and post-exposure influenza. Four antiviral drugs are available for the prevention and treatment of ...
- Cidara stock rallies amid $240M private placement, drug update
Shares of Cidara Therapeutics (NASDAQ:CDTX) rallied 25% in post-market trading Wednesday after the company announced it had reacquired the rights to its antiviral drug CD388 and agreed to a $240M ...
Go deeper with Google Headlines on:
Antiviral drug
[google_news title=”” keyword=”antiviral drug” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]